Ποια είναι η τιμή για Coeptis Therapeutics Holdings, Inc. (COEP)

Η τιμή για Coeptis Therapeutics Holdings, Inc. (COEP) είναι $4.81

Ποια είναι η κεφαλαιοποίηση αγοράς για Coeptis Therapeutics Holdings, Inc. (COEP)

Η κεφαλαιοποίηση αγοράς για Coeptis Therapeutics Holdings, Inc. (COEP) είναι $29.01M

Coeptis Therapeutics Holdings, Inc. (COEP) Τιμή και Κεφαλαιοποίηση Αγοράς

Coeptis Therapeutics Holdings, Inc., together with its subsidiaries, operates as a biopharmaceutical and technology company. The company is developing cell therapy platforms for cancer, autoimmune, and infectious diseases. Its therapeutic portfolio includes an allogeneic cellular immunotherapy platform; and DVX201, a clinical-stage, unmodified natural killer cell therapy technology. The company’s product pipeline consists of CD38-GEAR-NK, a cell therapy for the treatment of CD38-related cancers, including multiple myeloma, chronic lymphocytic leukemia, and acute myeloid leukemia; CD38-Diagnostic, an in vitro screening tool to analyze cancer patients if cancer patients might be appropriate candidates for anti-CD38 mAb therapy; and SNAP-CAR, a chimeric antigen receptor (CAR) therapy for treatment for cancer. In addition, the company offers its drugs for acute myeloid leukemia and acute respiratory diseases. Coeptis Therapeutics Holdings, Inc. has co-development agreement Vici Health Sciences, LLC to co-develop and share ownership rights to CPT60621 for the treatment of Parkinson’s Disease. The company was founded in 2017 and is headquartered in Wexford, Pennsylvania.

Η τιμή για COEP	Το περιουσιακό στοιχείο B	Η κεφαλαιοποίηση αγοράς του B	Αποτελέσματα
$878,706 $29.01M	NVDA	$5.301T	+18,268,214.14%
$768,140 $29.01M	AAPL	$4.634T	+15,969,540.85%
$686,767 $29.01M	GOOG	$4.143T	+14,277,802.18%
$594,997 $29.01M	MSFT	$3.589T	+12,369,909.84%
$473,586 $29.01M	AMZN	$2.857T	+9,845,765.86%

Η τιμή για COEP

Το περιουσιακό στοιχείο B

Η κεφαλαιοποίηση αγοράς του B

Αποτελέσματα

$878,706 $29.01M